ATE424211T1 - Therapeutische verwendung von sapogeninen - Google Patents
Therapeutische verwendung von sapogeninenInfo
- Publication number
- ATE424211T1 ATE424211T1 AT03722713T AT03722713T ATE424211T1 AT E424211 T1 ATE424211 T1 AT E424211T1 AT 03722713 T AT03722713 T AT 03722713T AT 03722713 T AT03722713 T AT 03722713T AT E424211 T1 ATE424211 T1 AT E424211T1
- Authority
- AT
- Austria
- Prior art keywords
- cognitive
- sapogenins
- therapeutic use
- neurodegeneration
- neuromuscular
- Prior art date
Links
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000001149 cognitive effect Effects 0.000 abstract 3
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 230000002232 neuromuscular Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP020101170A AR033079A1 (es) | 2001-03-28 | 2002-03-27 | Derivados de sapogeninas, sintesis y uso, y metodos en base a su uso |
| US36817802P | 2002-03-28 | 2002-03-28 | |
| PCT/GB2002/001578 WO2002079221A2 (en) | 2001-03-28 | 2002-03-28 | Sapogenin derivatives, their synthesis and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE424211T1 true ATE424211T1 (de) | 2009-03-15 |
Family
ID=30001210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03722713T ATE424211T1 (de) | 2002-03-27 | 2003-03-27 | Therapeutische verwendung von sapogeninen |
Country Status (10)
| Country | Link |
|---|---|
| KR (1) | KR20100093621A (de) |
| CN (1) | CN1642558B (de) |
| AT (1) | ATE424211T1 (de) |
| IL (1) | IL164161A0 (de) |
| NZ (2) | NZ547344A (de) |
| PE (1) | PE20040306A1 (de) |
| PL (1) | PL213697B1 (de) |
| RU (1) | RU2332999C2 (de) |
| TW (1) | TWI329016B (de) |
| WO (1) | WO2003082893A2 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861788B2 (en) * | 2003-06-03 | 2005-03-01 | Motorola, Inc. | Switchable display/mirror method and apparatus |
| FR2868700B1 (fr) * | 2004-04-09 | 2008-09-26 | Michel Coisy | Utilisation de la dopamine ou de ses precurseurs biologiques contre l'algoneurodystrphie. |
| GB0409567D0 (en) | 2004-04-28 | 2004-06-02 | Phytopharm Plc | Chemical compounds |
| GB0424528D0 (en) | 2004-11-05 | 2004-12-08 | Phytopharm Plc | Chemical compounds |
| RU2430737C2 (ru) | 2005-10-28 | 2011-10-10 | Сон-Ю КИМ | Экстракт семейства диоскорейных (dioscoreaceae) и содержащая его композиция для профилактики или лечения периферической невропатии |
| WO2010084356A1 (en) | 2009-01-24 | 2010-07-29 | Phytopharm Plc | Treatment of neurotrophic factor mediated disorders |
| RU2402325C1 (ru) * | 2009-02-02 | 2010-10-27 | Государственное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" | Способ лечения нейрососудистых осложнений сахарного диабета |
| MX2013000760A (es) * | 2010-07-20 | 2013-10-28 | Phytopharm Plc | Tratamiento de trastornos inducidos por l-dopa, agonista de la dopamina y/o potenciador de dopamina. |
| CN107936076B (zh) | 2011-09-08 | 2021-10-15 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| CU20110244A7 (es) * | 2011-12-27 | 2013-08-29 | Ct De Investigación Y Desarrollo De Medicamentos Cidem | Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios |
| US11319338B2 (en) | 2012-04-03 | 2022-05-03 | Goldporp Pharma Limited | Timosaponin compounds |
| MX362544B (es) | 2013-03-13 | 2019-01-24 | Sage Therapeutics Inc | Esteroides neuroactivos y metodos para su uso. |
| CN103232520A (zh) * | 2013-05-13 | 2013-08-07 | 中国药科大学 | 一种螺甾类化合物、其制备方法及医药用途 |
| EP4306114A1 (de) | 2014-06-18 | 2024-01-17 | Sage Therapeutics, Inc. | Oxysterole und verfahren zu ihrer verwendung |
| HK1255500A1 (zh) | 2015-07-06 | 2019-08-16 | Sage Therapeutics, Inc. | 氧固醇及其使用方法 |
| EP3828194B1 (de) | 2015-07-06 | 2025-04-16 | Sage Therapeutics, Inc. | Oxysterole und verfahren zur verwendung davon |
| PL3319612T3 (pl) | 2015-07-06 | 2021-12-20 | Sage Therapeutics, Inc. | Oksysterole i sposoby ich stosowania |
| US20190330259A1 (en) | 2016-04-01 | 2019-10-31 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| MD3481846T2 (ro) | 2016-07-07 | 2021-11-30 | Sage Therapeutics Inc | 24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA |
| CN121085986A (zh) | 2016-09-30 | 2025-12-09 | 萨奇治疗股份有限公司 | C7取代的氧固醇及其作为nmda调节剂的方法 |
| TW202444381A (zh) | 2016-10-18 | 2024-11-16 | 美商賽吉醫療公司 | 氧固醇(oxysterol)及其使用方法 |
| KR102521573B1 (ko) | 2016-10-18 | 2023-04-14 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| CN108264535A (zh) | 2016-12-30 | 2018-07-10 | 中国科学院上海药物研究所 | 一种抗抑郁化合物及其制备方法和应用 |
| RU2635485C1 (ru) * | 2017-03-21 | 2017-11-13 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ лечения атрофии зрительного нерва после черепно-мозговой травмы |
| CN109988218B (zh) * | 2017-12-29 | 2022-11-25 | 中国科学院上海药物研究所 | 一种菝葜皂苷元衍生物及其制备方法和应用 |
| EP3572085A1 (de) * | 2018-05-25 | 2019-11-27 | Neuro-Sys | Synergistische kombinationszusammensetzung mit einem steroidalen saponin, einer ersten polyphenolverbindung und gegebenenfalls einer zweiten polyphenolverbindung |
| CN112457362B (zh) * | 2019-09-06 | 2023-09-19 | 上海青东生物科技有限公司 | 一种卤代四环三萜衍生物及其制备与应用 |
| WO2023205801A2 (en) | 2022-04-22 | 2023-10-26 | Asteroid Therapeutics | Steroidal compositions and methods of treating lipogenic cancers |
| CN118994294A (zh) * | 2024-08-08 | 2024-11-22 | 吉林农业大学 | 薤白中新甾体皂苷的分离鉴定及应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3416112A1 (de) * | 1984-04-30 | 1985-10-31 | Roecar Holdings (Netherlands Antilles) N.V., Willemstad, Curacao, Niederländische Antillen | Verwendung von sterolinen und spiroketalinen als lipoxygenaseregulatoren |
| US4680289A (en) * | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
| JPH05246866A (ja) * | 1992-03-06 | 1993-09-24 | Ruibosuteii Japan:Kk | 脳代謝促進・脳機能改善剤 |
| DE4303214A1 (de) * | 1993-02-04 | 1994-08-11 | Wolfgang Marks | Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone |
| TW479061B (en) * | 1993-12-24 | 2002-03-11 | Mitsubishi Chem Corp | Sialic acid derivatives |
| JPH092956A (ja) * | 1995-06-22 | 1997-01-07 | Mitsubishi Chem Corp | 神経障害の治療、予防薬 |
| JPH092957A (ja) * | 1995-06-22 | 1997-01-07 | Mitsubishi Chem Corp | 末梢性神経障害の治療、予防薬 |
| US6046185A (en) * | 1996-07-11 | 2000-04-04 | Inflazyme Pharmaceuticals Ltd. | 6,7-oxygenated steroids and uses related thereto |
| CN1131237C (zh) * | 1997-09-26 | 2003-12-17 | 中国人民解放军军事医学科学院放射医学研究所 | 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙 |
| HUP0101693A3 (en) * | 1998-03-26 | 2002-08-28 | Phytopharm Plc Godmanchester | Use of steroidal sapogenins and their derivatives for producing pharmaceutical compositions for the treatment of alzheimeirs disease |
| GB9923076D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| GB9923078D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| GB9923077D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| GB0000228D0 (en) * | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| JP2002030096A (ja) * | 2000-07-11 | 2002-01-29 | Kyorin Pharmaceut Co Ltd | 神経細胞突起再生剤及びその製造方法 |
| JP2005526077A (ja) * | 2002-03-15 | 2005-09-02 | サマリタン・ファーマシューティカルズ・インコーポレイテッド | 神経防御性スピロステノール医薬組成物 |
-
2003
- 2003-03-27 NZ NZ547344A patent/NZ547344A/en unknown
- 2003-03-27 PL PL372941A patent/PL213697B1/pl not_active IP Right Cessation
- 2003-03-27 WO PCT/GB2003/001380 patent/WO2003082893A2/en not_active Ceased
- 2003-03-27 CN CN038071886A patent/CN1642558B/zh not_active Expired - Fee Related
- 2003-03-27 TW TW092106926A patent/TWI329016B/zh not_active IP Right Cessation
- 2003-03-27 NZ NZ547897A patent/NZ547897A/en unknown
- 2003-03-27 KR KR1020107017081A patent/KR20100093621A/ko not_active Abandoned
- 2003-03-27 AT AT03722713T patent/ATE424211T1/de active
- 2003-03-27 IL IL16416103A patent/IL164161A0/xx unknown
- 2003-03-27 RU RU2004130281/15A patent/RU2332999C2/ru not_active IP Right Cessation
- 2003-03-27 PE PE2003000315A patent/PE20040306A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200400042A (en) | 2004-01-01 |
| KR20100093621A (ko) | 2010-08-25 |
| NZ547344A (en) | 2007-11-30 |
| TWI329016B (en) | 2010-08-21 |
| RU2332999C2 (ru) | 2008-09-10 |
| WO2003082893A2 (en) | 2003-10-09 |
| PE20040306A1 (es) | 2004-05-29 |
| WO2003082893A3 (en) | 2004-04-15 |
| CN1642558B (zh) | 2012-05-30 |
| RU2004130281A (ru) | 2006-01-20 |
| IL164161A0 (en) | 2005-12-18 |
| CN1642558A (zh) | 2005-07-20 |
| PL372941A1 (en) | 2005-08-08 |
| WO2003082893A8 (en) | 2003-12-31 |
| PL213697B1 (pl) | 2013-04-30 |
| NZ547897A (en) | 2008-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE424211T1 (de) | Therapeutische verwendung von sapogeninen | |
| TR200700134T1 (tr) | Sapogenin türevleri, bunların sentezi ve kullanımı, bunların kullanım metotları. | |
| DE60137307D1 (de) | Substituierte sapogenine und ihre verwendung | |
| DE60314500D1 (de) | Diaminopyrimidine und deren verwendung als angiogenesehemmer | |
| EP1484366A4 (de) | Behandeltes pigment, dessen verwendung und verbindung zur behandlung von pigmenten | |
| ATE507834T1 (de) | Sarsasapogenin und smilagenin zur behandlung kognitiver störungen | |
| BR0309665A (pt) | Tratamento de deficiência de alfa-galactosidase a | |
| ATE325808T1 (de) | 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz | |
| DE60118544D1 (de) | Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren | |
| TW200528117A (en) | Methods and reagents for the treatment of proliferative diseases | |
| DE60108857D1 (de) | Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren | |
| WO2004084943A8 (en) | Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation | |
| TR200101149T2 (tr) | Dış retina bozukluklarının tedavisi. | |
| GB9923078D0 (en) | Sapogenin derivatives and their use | |
| HRP20041009A2 (en) | Theraputic methods and uses of sapogenins and their derivatives | |
| TW200833344A (en) | Therapeutic methods and uses of sapogenins and their derivatives | |
| DE50205438D1 (de) | Verwendung von buprenorphin zur therapie der harninkontinenz | |
| BR0308788A (pt) | Processos terapêuticos e usos de sapogeninas e seus derivados | |
| MY134920A (en) | 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia | |
| WO2004073631A3 (en) | Combination therapy for the treatment of neoplasms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1490071 Country of ref document: EP |